


RECEIVED  
CENTRAL FAX CENTER

ATTORNEYS AT LAW

1840 DUKE STREET  
ALEXANDRIA, VIRGINIA 22314(703) 413-3000  
(703) 413-2220 FACSIMILE  
OBLONPAT@OBLON.COM  
WWW.OBLON.COM

## FACSIMILE

NOV 12 2004

PLEASE CALL US AT (703) 413-3000 IF THE MESSAGE YOU RECEIVE IS INCOMPLETE OR NOT LEGIBLE

I hereby certify that this correspondence is being facsimile transmitted to:

Commissioner for Patents  
Alexandria, VA 22313-1450  
(703) 872-9306

on Date:

11/12/04

Signature:

  
Frederick D. Vastine, Ph.D.

Total number of pages including this page: 10

OSMM&N File No. 216008US0PCTDept.: ChemicalBy: NRQ/FDV/eswSerial No. 09/926.679In the matter of the Application of: Fumiaki IKEDA, et al.For: ANTIFUNGAL COMBINATION USEDue Date: n/a

- ☐ Dep. Acct. Order Form
- ☐ Amendment Cover Letter
- ☐ Supplemental Amendment

Unless otherwise indicated or obvious from the nature of the transmittal, the information contained in this facsimile message is attorney privileged and confidential information intended for the use of the individual or entity named above. If the reader of this message is not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error or are not sure whether it is privileged, please immediately notify us by telephone and return the original message to us at the above address via the U.S. Postal Service at our Expense. Thank You.

Docket No. 216008US0PCT  
 IN RE APPLICATION OF: Fumiaki IKEDA, et al  
 SERIAL NO: 09/926,679  
 FILED: November 30, 2001  
 FOR: ANTIFUNGAL COMBINATION USE

**RECEIVED**  
**CENTRAL FAX CENTER**

NOV 12 2004

COMMISSIONER FOR PATENTS  
 ALEXANDRIA, VIRGINIA 22313

SIR:

Transmitted herewith is a Supplemental Amendment in the above-identified application.

- ☒ No additional fee is required  
☐ Small entity status of this application under 37 C.F.R. §1.9 and §1.27 is claimed.  
☐ Additional documents filed herewith:

The Fee has been calculated as shown below:

CLAIMS	CLAIMS REMAINING		HIGHEST NUMBER PREVIOUSLY PAID	NO. EXTRA CLAIMS	RATE	CALCULATIONS
TOTAL	12	MINUS	20	0	x \$18 =	\$0.00
INDEPENDENT	1	MINUS	3	0	x \$88 =	\$0.00
<input type="checkbox"/> MULTIPLE DEPENDENT CLAIMS					+ \$300 =	\$0.00
TOTAL OF ABOVE CALCULATIONS						\$0.00
<input type="checkbox"/> Reduction by 50% for filing by Small Entity						\$0.00
<input type="checkbox"/> Recordation of Assignment					+ \$40 =	\$0.00
TOTAL						\$0.00

- ☐ A check in the amount of \$0.00 is attached.  
☐ Credit card payment form is attached to cover the fees in the amount of \$0.00  
☒ Please charge any additional Fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit Account No. 15-0030. A duplicate copy of this sheet is enclosed.  
☒ If these papers are not considered timely filed by the Patent and Trademark Office, then a petition is hereby made under 37 C.F.R. §1.136, and any additional fees required under 37 C.F.R. §1.136 for any necessary extension of time may be charged to Deposit Account No. 15-0030. A duplicate copy of this sheet is enclosed.

OBLON, SPIVAK, McCLELLAND,  
 MAIER & NEUSTADT, P.C.  
 Norman F. Oblon

*FD Vastine*  
 Frederick D. Vastine, Ph.D.  
 Registration No. 27,013

Customer Number

**22850**

Tel. (703) 413-3000  
 Fax. (703) 413-2220  
 (OSMMN 05/03)

Appln. No. 09/926,679  
Supplemental Amendment

**RECEIVED**  
**CENTRAL FAX CENTER**

NOV 12 2004

DOCKET NO: 216008US0PCT

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE APPLICATION OF :  
FUMIAKI IKEDA, ET AL. : EXAMINER: MOHAMED, A.  
SERIAL NO: 09/926,679 :  
FILED: NOVEMBER 30, 2001 : GROUP ART UNIT: 1653  
FOR: ANTIFUNGAL COMBINATION :  
USE :

SUPPLEMENTAL AMENDMENT

COMMISSIONER FOR PATENTS  
P. O. BOX 1450  
ALEXANDRIA, VIRGINIA 22313-1450

SIR:

Please amend the above-identified application as follows:

Amendments to the Claims are reflected in the listing of claims which begins on  
page 2 of this paper.

Remarks/Arguments begin on page 7 of this paper.